Stipple Bio Emerges From Stealth with $100M Series A
2026-04-06
Tweet
CAMBRIDGE, MA, Stipple Bio, a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, announced the close of a $100 million Series A financing.
Stipple Bio, a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, announced the close of a $100 million heavily oversubscribed Series A financing.
The financing was co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners and GordonMD Global Investments, among others. In conjunction with the financing, Derek DiRocco, PhD and Thilo Schroeder, PhD will join the Stipple Bio Board of Directors which already includes Vineeta Agarwala MD, PhD, Owen Hughes, Jeff Landau and Aaron Ring MD, PhD and Greg Verdine, PhD.
The financing was co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners and GordonMD Global Investments, among others. In conjunction with the financing, Derek DiRocco, PhD and Thilo Schroeder, PhD will join the Stipple Bio Board of Directors which already includes Vineeta Agarwala MD, PhD, Owen Hughes, Jeff Landau and Aaron Ring MD, PhD and Greg Verdine, PhD.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
